Prosecution Insights
Last updated: April 19, 2026

Rottapharm Biotech S R L

1 pending office actions

Portfolio Summary

1
Total Pending OAs
0
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18387577 Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease BARSKY, JARED 1628 Non-Final OA Nov 07, 2023

Managing Rottapharm Biotech S R L's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month